| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA41378
Max Phase: Preclinical
Molecular Formula: C14H26N2O6
Molecular Weight: 228.34
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CC(C)NCC(O)CON=C1CCCCC1.O=C(O)C(=O)O
Standard InChI: InChI=1S/C12H24N2O2.C2H2O4/c1-10(2)13-8-12(15)9-16-14-11-6-4-3-5-7-11;3-1(4)2(5)6/h10,12-13,15H,3-9H2,1-2H3;(H,3,4)(H,5,6)
Standard InChI Key: HEXYKEJOOSLEJQ-UHFFFAOYSA-N
Associated Targets(Human)
ADRB1 Tclin Adrenergic receptor beta; ADRB1 & ADRB2 (240 Activities)
Associated Targets(non-human)
ADRB1 Beta-1 adrenergic receptor (895 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Adrb2 Beta-2 adrenergic receptor (1382 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 228.34 | Molecular Weight (Monoisotopic): 228.1838 | AlogP: 1.68 | #Rotatable Bonds: 6 |
| Polar Surface Area: 53.85 | Molecular Species: BASE | HBA: 4 | HBD: 2 |
| #RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 9.86 | CX LogP: 1.65 | CX LogD: -0.74 |
| Aromatic Rings: 0 | Heavy Atoms: 16 | QED Weighted: 0.68 | Np Likeness Score: -0.47 |
References
| 1. Macchia B, Balsamo A, Lapucci A, Martinelli A, Macchia F, Breschi MC, Fantoni B, Martinotti E.. (1985) An interdisciplinary approach to the design of new structures active at the beta-adrenergic receptor. Aliphatic oxime ether derivatives., 28 (2): [PMID:2857200] [10.1021/jm00380a001] |
| 2. Leclerc G, Bieth N, Schwartz J.. (1980) Synthesis and beta-adrenergic blocking activity of new aliphatic oxime ethers., 23 (6): [PMID:6104730] [10.1021/jm00180a007] |
Source
Source(1):